Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP March 2015: BI-Lilly closes in on diabetes fray

This article was originally published in Scrip

Executive Summary

On 27 March 2015, the European Medicines Agency's advisors gave the BI-Lilly Diabetes Alliance a little push forward, voting in favor of Synjardy, its fixed dose combination (FDC) of SGLT2 inhibitor Jardiance (empagliflozin) with metformin for treating Type 2 diabetes mellitus. But while the decision in Europe is important, Europe is not a big market for FDC products in diabetes. BI-Lilly's real battle in the SGLT2 market will be fought around the long-term safety data of SGLT2 compounds and on their efficacy when combined in fixed doses with gliptins.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028265

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel